^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    JNJ-6665

    i
    Other names: JNJ-74856665, JNJ74856665, JNJ-6665
    Associations

    News

    Trials
    Company:
    J&J
    Drug class:
    DHODH inhibitor
    Related drugs:
    Associations

    News

    Trials
    4d
    Potent synergy of DHODH and SREBP inhibition in acute myeloid leukemia via disruption of cholesterol and lipid metabolism. (PubMed, Haematologica)
    Here, we describe a novel DHODH inhibitor, JNJ-74856665, that showed strong efficacy in a subset of AML samples. The transcriptional regulator SREBF2, known to control cholesterol and lipid metabolism, was upregulated in DHODHi sensitive AMLs, and a strong synergy was observed between combination of both DHODHi and the SREBP inhibitor dipyridamole. Our data indicate that combined DHODH and SREBP inhibition is of interest to explore further as a therapeutic target option in AML.
    Journal
    |
    SREBF2 (Sterol Regulatory Element Binding Transcription Factor 2)
    |
    JNJ-6665
    2ms
    A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) (clinicaltrials.gov)
    P1, N=153, Completed, Janssen Research & Development, LLC | Active, not recruiting --> Completed
    Trial completion
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    JNJ-6665
    11ms
    A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring (clinicaltrials.gov)
    P1, N=80, Enrolling by invitation, Janssen Research & Development, LLC
    New P1 trial
    |
    Imbruvica (ibrutinib) • safimaltib (JNJ-6633) • JNJ-4681 • JNJ-6665 • JNJ-8902 • onametostat (JNJ-64619178) • rezetamig (JNJ-8780)
    1year
    A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) (clinicaltrials.gov)
    P1, N=153, Active, not recruiting, Janssen Research & Development, LLC | Trial completion date: Jul 2024 --> Jul 2025 | Trial primary completion date: Jul 2024 --> Jul 2025
    Trial completion date • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    JNJ-6665
    almost2years
    A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) (clinicaltrials.gov)
    P1, N=155, Active, not recruiting, Janssen Research & Development, LLC | Trial completion date: Dec 2023 --> Jul 2024 | Trial primary completion date: Dec 2023 --> Jul 2024
    Trial completion date • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    JNJ-6665
    over2years
    A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) (clinicaltrials.gov)
    P1, N=157, Active, not recruiting, Janssen Research & Development, LLC | Trial completion date: Aug 2023 --> Dec 2023 | Trial primary completion date: Feb 2023 --> Dec 2023
    Trial completion date • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    JNJ-6665
    3years
    A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) (clinicaltrials.gov)
    P1, N=157, Active, not recruiting, Janssen Research & Development, LLC | Trial completion date: Dec 2024 --> Aug 2023 | Trial primary completion date: Sep 2023 --> Feb 2023
    Trial completion date • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    JNJ-6665
    over3years
    A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) (clinicaltrials.gov)
    P1, N=157, Active, not recruiting, Janssen Research & Development, LLC | Recruiting --> Active, not recruiting | N=281 --> 157
    Enrollment closed • Enrollment change
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    JNJ-6665
    over3years
    A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) (clinicaltrials.gov)
    P1, N=281, Recruiting, Janssen Research & Development, LLC | Trial completion date: Jun 2024 --> Dec 2024
    Trial completion date
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    JNJ-6665
    4years
    A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) (clinicaltrials.gov)
    P1, N=281, Recruiting, Janssen Research & Development, LLC | N=120 --> 281 | Trial completion date: Sep 2023 --> Jun 2024
    Enrollment change • Trial completion date
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    JNJ-6665
    almost5years
    [VIRTUAL] JNJ-74856665, a novel DHODH inhibitor, mediates potent anti-leukemic activity and differentiation in vitro and in vivo (AACR 2021)
    Combination of JNJ-74856665 with azacitidine in vivo demonstrated lack of antagonism in the anti-leukemic activity.The results described herein demonstrate that JNJ-74856665 exerts potent anti-leukemic activity in vitro and in vivo and warrant further investigation. To that end, a phase 1 clinical trial assessing the safety and efficacy of JNJ-74856665 in patients with AML and MDS is planned to initiate shortly.
    Preclinical
    |
    CD14 (CD14 Molecule) • ITGAM (Integrin, alpha M)
    |
    azacitidine • JNJ-6665